SCHEMBL3534707

SCHEMBL3534707

CCOC(=O)CNC(=O)c1c(O)c(-c2cccc(F)c2)cc2nc(-c3nccs3)cnc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN3 Q9H6Z9 1/20 0.41
KDM4E B2RXH2 2/20 0.40
TRPM8 Q7Z2W7 1/20 0.38
ADORA2A P29274 2/20 0.36
ADORA1 P30542 2/20 0.36
LMNA P02545 2/20 0.36
HCRTR2 O43614 1/20 0.35
PPID Q08752 1/20 0.35
MAPT P10636 3/20 0.35
HPGD P15428 3/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CYP1A2 P05177 1/20 0.35
GAA P10253 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
KMT2A Q03164 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
TOP2A P11388 1/20 0.35
THRB P10828 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3526608 0.89 EGLN3 (0.53) EGLN3KDM4EADORA2AADORA1CYP1A2
SCHEMBL3520781 0.88 EGLN3 (0.38) EGLN3KDM4ELMNAHCRTR2MAPT
SCHEMBL3520873 0.86 EGLN3 (0.40) EGLN3KDM4ETRPM8LMNAPPID
SCHEMBL3526639 0.85 EGLN3 (0.36) EGLN3KDM4ELMNAHCRTR2HPGD
SCHEMBL3532359 0.82 LMNA (0.37) EGLN3KDM4ELMNAMAPTHPGD
SCHEMBL3526186 0.82 KMO (0.40) EGLN3KDM4EADORA2AADORA1HPGD
SCHEMBL3761491 0.81 EGLN3 (0.45) EGLN3LMNAHPGDALDH1A1L3MBTL1
SCHEMBL3518821 0.81 EGLN3 (0.49) EGLN3KDM4ELMNAPPIDMAPT
SCHEMBL3519757 0.80 EGLN3 (0.38) EGLN3KDM4ELMNAHPGDMEN1
SCHEMBL3520006 0.80 EGLN3 (0.43) EGLN3KDM4ETRPM8LMNAPPID

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 EGLN3 2/4885KDM4E 176/4885TRPM8 4844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.